| 週次 |
授課內容 |
| 第1週 |
Part I: Foundations
Chapter 2 - Neurons and Glia
|
| 第2週 |
Chapter 3 - Neuronal Membrane at Rest
|
| 第3週 |
Chapter 4 - The Action Potential |
| 第4週 |
Chapter 5 - Synaptic Transmission |
| 第5週 |
Chapter 6 - Neurotransmitter Systems |
| 第6週 |
Chapter 7 - The Structure of the Nervous System (Human Neuroanatomy) |
| 第7週 |
Part 2 Sensory and Motor Systems
Chapter 13 - Spinal Control of Movement |
| 第8週 |
Chapter 14 - Brain Control of Movement |
| 第9週 |
Part 3 The Brain and Behavior
Chapter 15 - Chemical Control of the Brain and Behavior
|
| 第10週 |
Part 4 The Changing Brain
Chapter 24 - Memory Systems |
| 第11週 |
Chapter 25 - Molecular Mechanisms of Learning and Memory
|
| 第12週 |
Final examination |
| 第13週 |
Part 5. Applications of Cellular and Animal Models and Biomarker Development in Neurodegenerative Diseases
1. Alzheimer’s disease
Please describe commonly used cellular and animal models of Alzheimer’s disease, such as APP/PS1 mice or Aβ-treated neuronal cell models. How can these models be used to study Aβ deposition, tau pathology, neuroinflammation, and cognitive decline? In addition, discuss how Aβ, total tau, phosphorylated tau, or neurofilament light chain may serve as biomarkers for disease diagnosis and progression. |
| 第14週 |
Part 5. Applications of Cellular and Animal Models and Biomarker Development in Neurodegenerative Diseases
2. Parkinson’s disease
Using MPTP, 6-OHDA animal models, or α-synuclein overexpression models as examples, explain how these models mimic dopaminergic neuron degeneration, motor dysfunction, and α-synuclein aggregation. Further discuss the potential and limitations of α-synuclein, dopamine metabolites, or inflammatory cytokines as biomarkers for Parkinson’s disease. |
| 第15週 |
Part 5. Applications of Cellular and Animal Models and Biomarker Development in Neurodegenerative Diseases
3. Huntington’s disease
Using R6/2 mice, STHdhQ7/Q111 cells, or mutant huntingtin overexpression models as examples, explain how these models are used to study mHTT aggregation, striatal neuron degeneration, autophagy–lysosomal dysfunction, and neuroinflammation. Discuss the application of mHTT, neurofilament light chain, cytokines, or imaging biomarkers in evaluating disease progression in Huntington’s disease. |
| 第16週 |
Part 5. Applications of Cellular and Animal Models and Biomarker Development in Neurodegenerative Diseases
4. Amyotrophic lateral sclerosis
Please describe how SOD1-G93A mice, TDP-43 models, or iPSC-derived motor neurons are used to study motor neuron degeneration, protein aggregation, axonal degeneration, and glial activation. Discuss the clinical value of neurofilament light chain, TDP-43, GFAP, or inflammatory markers as biomarkers for ALS. |
自主學習
內容 |
02.閱覽產業及學術相關多媒體資料
03.製作專題報告
|